Neuroone Medical Technologies
NASDAQ: NMTCEden Prairie, US · Delaware corporation
Founders & leadership
RM
Ronald McClurgExecutive
MC
Mark ChristiansonExecutive
SM
Steve MertensExecutive
CV
Christopher VolkerExecutive
DA
David A. RosaNamed on SEC filing
TB
Thomas BachinskiNamed on SEC filing
AS
Amer SamadNamed on SEC filing
Board
JS
Jeffrey S. MathiesenBoard director
PB
Paul BuckmanBoard director
EA
Edward AndrleBoard director
Reported raises · per SEC filings
Form D private placements$21.2M disclosed across 10 of 11 rounds · 2017–2024
▶$276KraisedAug 2024 · 20 investors · BiotechnologyRule 506(b)
▶$276KraisedAug 2024 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. MathiesenDirector
- Ronald McClurgExecutive Officer
- Paul BuckmanDirector
- David A. RosaExecutive Officer, Director
- Edward AndrleDirector
- Mark ChristiansonExecutive Officer
- Steve MertensExecutive Officer
- Christopher VolkerExecutive Officer
- Offering amount
- $276K
- Amount sold
- $276K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.5MraisedJan 2021 · 36 investors · BiotechnologyRule 506(b)
▶$12.5MraisedJan 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward AndrleDirector
- Ronald McClurgExecutive Officer
- Paul BuckmanDirector
- Steve MertensExecutive Officer
- Mark ChristiansonExecutive Officer
- David A. RosaExecutive Officer, Director
- Jeffrey S. MathiesenDirector
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- Sales commissions
- $1M
- Proceeds to insiders
- $1.4M
- Placement agents
- The Benchmark Company, LLC
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$135KraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
▶$135KraisedAug 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward AndrleDirector
- Jeffrey S. MathiesenDirector
- David A. RosaExecutive Officer, Director
- Paul BuckmanDirector
- Mark ChristiansonExecutive Officer
- Steve MertensExecutive Officer
- Offering amount
- $135K
- Amount sold
- $135K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedMay 2020 · 33 investors · BiotechnologyRule 506(b)
▶$2.5MraisedMay 2020 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ChristiansonExecutive Officer
- Steve MertensExecutive Officer
- Jeffrey S. MathiesenDirector
- David A. RosaExecutive Officer, Director
- Paul BuckmanDirector
- Edward AndrleDirector
- Offering amount
- $6M
- Amount sold
- $2.5M
- Minimum investment
- $25K
- Sales commissions
- $360K
- Proceeds to insiders
- $943K
- Placement agents
- Paulson Investment Company
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$255KraisedNov 2019 · 3 investors · BiotechnologyRule 506(b)
▶$255KraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David A. RosaExecutive Officer, Director
- Mark ChristiansonExecutive Officer
- Jeffrey S. MathiesenDirector
- Suraj KaliaDirector
- Paul BuckmanDirector
- Steve MertensExecutive Officer
- Offering amount
- $1M
- Amount sold
- $255K
- Minimum investment
- $25K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedNov 2019 · 16 investors · BiotechnologyRule 506(b)
▶$1.3MraisedNov 2019 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve MertensExecutive Officer
- Jeffrey S. MathiesenDirector
- Suraj KaliaDirector
- Paul BuckmanDirector
- Mark ChristiansonExecutive Officer
- David A. RosaExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- Sales commissions
- $240K
- Proceeds to insiders
- $976K
- Placement agents
- Paulson Investment Company
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedFeb 2019 · 21 investors · BiotechnologyRule 506(b)
▶$1.5MraisedFeb 2019 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas BachinskiExecutive Officer
- Suraj KaliaDirector
- David A. RosaExecutive Officer, Director
- Jeffrey S. MathiesenDirector
- Mark ChristiansonExecutive Officer
- Paul BuckmanDirector
- Offering amount
- $10M
- Amount sold
- $1.5M
- Sales commissions
- $90.2K
- Proceeds to insiders
- $823.1K
- Placement agents
- Mohammad Jainal Bhuiyan
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$992.5KraisedFeb 2019 · 17 investors · BiotechnologyRule 506(b)
▶$992.5KraisedFeb 2019 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul BuckmanDirector
- Jeffrey S. MathiesenDirector
- David A. RosaExecutive Officer, Director
- Thomas BachinskiExecutive Officer
- Suraj KaliaDirector
- Mark ChristiansonExecutive Officer
- Offering amount
- $10M
- Amount sold
- $992.5K
- Sales commissions
- $1.2M
- Proceeds to insiders
- $823.1K
- Placement agents
- Mark Finckle, Mohammad Jainal Bhuiyan
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Neuroone Medical Technologies raised?
- Neuroone Medical Technologies has disclosed $21.2M raised across 10 of its 11 known rounds.
- Where is Neuroone Medical Technologies headquartered?
- Neuroone Medical Technologies is headquartered in Eden Prairie, US.